Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

$ 7.96 -0.07 (0.87%)
Day High: 8.11
Day Low:  7.88
Volume:    67,903
11:32 AM ET

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations